Australian Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Alterity Therapeutics

Market Cap: AU$119.6m

Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.

Cryosite

Market Cap: AU$41.0m

Provides outsourced clinical trials logistic services in Australia.

Starpharma Holdings

Market Cap: AU$96.2m

A biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications internationally.

CSL

Market Cap: AU$95.8b

Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.

Tetratherix

Market Cap: AU$208.9m

Engages in biomaterial and regenerative medicine business in Australia and internationally.

Imugene

Market Cap: AU$81.4m

A clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.

Mayne Pharma Group

Market Cap: AU$416.8m

A specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.

Aroa Biosurgery

Market Cap: AU$234.6m

Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

Race Oncology

Market Cap: AU$540.5m

A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments.

Vitura Health

Market Cap: AU$42.4m

Engages in the sale and distribution of medicinal cannabis products in Australia.

Tryptamine Therapeutics

Market Cap: AU$63.4m

A clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States.

Radiopharm Theranostics

Market Cap: AU$68.6m

A clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.

Cynata Therapeutics

Market Cap: AU$48.7m

Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

Botanix Pharmaceuticals

Market Cap: AU$294.2m

Operates as a commercial dermatology company in Australia and the United States.

Actinogen Medical

Market Cap: AU$98.4m

A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.

Genetic Technologies

Market Cap: AU$5.7m

A molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

BCAL Diagnostics

Market Cap: AU$25.6m

A screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer.

Percheron Therapeutics

Market Cap: AU$10.9m

Engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia.

NeuroScientific Biopharmaceuticals

Market Cap: AU$54.9m

Engages in the research and development of novel peptide-based pharmaceutical products.

Mesoblast

Market Cap: AU$3.2b

Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.